User contributions for Parth Vikram Singh
Results for Parth Vikram Singh talk block log uploads logs
A user with 1,557 edits. Account created on 28 January 2025.
24 April 2025
- 10:5410:54, 24 April 2025 diff hist +2,374 Loncastuximab tesirine-lpyl No edit summary
- 10:4810:48, 24 April 2025 diff hist +15,849 Loncastuximab tesirine-lpyl No edit summary
- 09:5909:59, 24 April 2025 diff hist +4,224 Loncastuximab tesirine-lpyl No edit summary
- 09:5309:53, 24 April 2025 diff hist +5,343 Loncastuximab tesirine-lpyl No edit summary
- 09:2409:24, 24 April 2025 diff hist +1,606 N Loncastuximab tesirine-lpyl Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |genericName=loncastuximab tesirine-lpyl |aOrAn=a |drugClass=CD19-directed antibody and alkylating agent |indicationType=treatment |indication=adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. |adverseReactions=thrombocytope..."
- 09:1909:19, 24 April 2025 diff hist +71 Pegcetacoplan No edit summary current
- 08:2408:24, 24 April 2025 diff hist −61 Pegcetacoplan No edit summary
- 08:0908:09, 24 April 2025 diff hist +3,925 Pegcetacoplan No edit summary
- 07:3307:33, 24 April 2025 diff hist +14,904 Pegcetacoplan No edit summary
- 02:3902:39, 24 April 2025 diff hist +3,793 Pegcetacoplan No edit summary
- 02:3202:32, 24 April 2025 diff hist +12,715 Pegcetacoplan No edit summary
23 April 2025
- 16:5916:59, 23 April 2025 diff hist +4,252 Pegcetacoplan No edit summary
- 14:5814:58, 23 April 2025 diff hist +2,906 N Pegcetacoplan Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |genericName=pegcetacoplan |aOrAn=a |drugClass=complement inhibitor |indicationType=treatment |indication=adult patients with paroxysmal nocturnal hemoglobinuria (PNH). |hasBlackBoxWarning=Yes |adverseReactions=injection-site reactions, infections, diarrhea, abdominal pain, respiratory tract infection, pain in extremity, hypokalemia, fatigue, viral infection, cough, arthralgia, dizziness, headache, and rash. |blackBoxWarning..."
- 14:5314:53, 23 April 2025 diff hist 0 N File:Empt6.png No edit summary current
- 14:5314:53, 23 April 2025 diff hist 0 N File:Empt5.png No edit summary current
- 14:5214:52, 23 April 2025 diff hist 0 N File:Empt4.png No edit summary current
- 14:5214:52, 23 April 2025 diff hist 0 N File:Empt3.png No edit summary current
- 14:5114:51, 23 April 2025 diff hist 0 N File:Empt2b.png No edit summary current
- 14:5114:51, 23 April 2025 diff hist 0 N File:Empt2a.png No edit summary current
- 14:5114:51, 23 April 2025 diff hist 0 N File:Empt1.png No edit summary current
- 14:5014:50, 23 April 2025 diff hist 0 N File:Empstr.png No edit summary current
- 14:5014:50, 23 April 2025 diff hist 0 N File:Emppkg1.png No edit summary current
- 14:4914:49, 23 April 2025 diff hist 0 N File:Emppkg.png No edit summary current
- 14:4914:49, 23 April 2025 diff hist 0 N File:Empf1.png No edit summary current
- 11:1911:19, 23 April 2025 diff hist +17,105 Amivantamab-vmjw No edit summary current
- 10:5610:56, 23 April 2025 diff hist +4,814 Amivantamab-vmjw No edit summary
- 10:4310:43, 23 April 2025 diff hist +290 Amivantamab-vmjw No edit summary
- 10:3710:37, 23 April 2025 diff hist 0 Amivantamab-vmjw No edit summary
- 10:3510:35, 23 April 2025 diff hist +1 Amivantamab-vmjw No edit summary
- 10:2210:22, 23 April 2025 diff hist +33,809 Amivantamab-vmjw No edit summary
- 07:1207:12, 23 April 2025 diff hist −8 Amivantamab-vmjw No edit summary
- 07:1007:10, 23 April 2025 diff hist −6 Amivantamab-vmjw No edit summary
- 06:2706:27, 23 April 2025 diff hist +2 Amivantamab-vmjw No edit summary
- 06:2406:24, 23 April 2025 diff hist +9,488 Amivantamab-vmjw No edit summary
- 05:0705:07, 23 April 2025 diff hist −13 Amivantamab-vmjw No edit summary
- 05:0505:05, 23 April 2025 diff hist +3,667 N Amivantamab-vmjw Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |genericName=amivantamab-vmjw |aOrAn=a |drugClass=bispecific EGF receptor |indicationType=treatment |indication=*adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. *in combination with carboplatin and pemetrexed for the treatment of adult patients wit..."
22 April 2025
- 18:1418:14, 22 April 2025 diff hist −2 Piflufolastat F 18 No edit summary current
- 18:1118:11, 22 April 2025 diff hist −354 Sotorasib No edit summary current
- 18:0118:01, 22 April 2025 diff hist −1,351 Infigratinib No edit summary current
- 17:4517:45, 22 April 2025 diff hist −524 Olanzapine and samidorphan No edit summary current
- 17:2417:24, 22 April 2025 diff hist −1 Vanzacaftor, tezacaftor, and deutivacaftor No edit summary current
- 17:2317:23, 22 April 2025 diff hist +219 Vanzacaftor, tezacaftor, and deutivacaftor No edit summary
- 16:5816:58, 22 April 2025 diff hist 0 N File:Rbyt20.png No edit summary current
- 16:5716:57, 22 April 2025 diff hist 0 N File:Rbyt19.png No edit summary current
- 16:5516:55, 22 April 2025 diff hist 0 N File:Rybt6.png No edit summary current
- 16:5516:55, 22 April 2025 diff hist 0 N File:Rybt5.png No edit summary current
- 16:5516:55, 22 April 2025 diff hist 0 N File:Rybt4.png No edit summary current
- 16:5416:54, 22 April 2025 diff hist 0 N File:Rybt3.png No edit summary current
- 16:5416:54, 22 April 2025 diff hist 0 N File:Rybt2.png No edit summary current
- 16:5416:54, 22 April 2025 diff hist 0 N File:Rybt1.png No edit summary current
